Intrinsic subtypes in Ethiopian breast cancer patient.
Breast cancer
Ethiopia
Intrinsic subtyping
PAM50
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
09
08
2022
accepted:
06
10
2022
pubmed:
26
10
2022
medline:
8
11
2022
entrez:
25
10
2022
Statut:
ppublish
Résumé
The recent development of multi-gene assays for gene expression profiling has contributed significantly to the understanding of the clinically and biologically heterogeneous breast cancer (BC) disease. PAM50 is one of these assays used to stratify BC patients and individualize treatment. The present study was conducted to characterize PAM50-based intrinsic subtypes among Ethiopian BC patients. Formalin-fixed paraffin-embedded tissues were collected from 334 BC patients who attended five different Ethiopian health facilities. All samples were assessed using the PAM50 algorithm for intrinsic subtyping. The tumor samples were classified into PAM50 intrinsic subtypes as follows: 104 samples (31.1%) were luminal A, 91 samples (27.2%) were luminal B, 62 samples (18.6%) were HER2-enriched and 77 samples (23.1%) were basal-like. The intrinsic subtypes were found to be associated with clinical and histopathological parameters such as steroid hormone receptor status, HER2 status, Ki-67 proliferation index and tumor differentiation, but not with age, tumor size or histological type. An immunohistochemistry-based classification of tumors (IHC groups) was found to correlate with intrinsic subtypes. The distribution of the intrinsic subtypes confirms previous immunohistochemistry-based studies from Ethiopia showing potentially endocrine-sensitive tumors in more than half of the patients. Health workers in primary or secondary level health care facilities can be trained to offer endocrine therapy to improve breast cancer care. Additionally, the findings indicate that PAM50-based classification offers a robust method for the molecular classification of tumors in the Ethiopian context.
Identifiants
pubmed: 36282363
doi: 10.1007/s10549-022-06769-z
pii: 10.1007/s10549-022-06769-z
pmc: PMC9633534
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-504Subventions
Organisme : Susan G. Komen
ID : GTDR16378013
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Feng Y, Spezia M, Huang S et al (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 5(2):77–106. https://doi.org/10.1016/j.gendis.2018.05.001
doi: 10.1016/j.gendis.2018.05.001
pubmed: 30258937
pmcid: 6147049
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
Joko-Fru WY, Griesel M, Mezger NCS et al (2021) Breast cancer diagnostics, therapy, and outcomes in Sub-Saharan Africa: a population-based registry study. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2021.7011
doi: 10.6004/jnccn.2021.7011
Timotewos G, Solomon A, Mathewos A et al (2018) First data from a population based cancer registry in Ethiopia. Cancer Epidemiol 53:93–98. https://doi.org/10.1016/j.canep.2018.01.008
doi: 10.1016/j.canep.2018.01.008
pubmed: 29414637
Kantelhardt EJ, Zerche P, Mathewos A et al (2014) Breast cancer survival in Ethiopia: a cohort study of 1070 women. Int J Cancer 135(3):702–709. https://doi.org/10.1002/ijc.28691
doi: 10.1002/ijc.28691
pubmed: 24375396
Eber-Schulz P, Tariku W, Reibold C et al (2018) Survival of breast cancer patients in rural Ethiopia. Breast Cancer Res Treat 170(1):111–118. https://doi.org/10.1007/s10549-018-4724-z
doi: 10.1007/s10549-018-4724-z
pubmed: 29479644
Gradishar WJ, Moran MS, Abraham J et al (2022) Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030
doi: 10.6004/jnccn.2022.0030
Andre F, Ismaila N, Allison KH et al (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol 40(16):1816–1837. https://doi.org/10.1200/JCO.22.00069
doi: 10.1200/JCO.22.00069
pubmed: 35439025
Giorgi Rossi P, Lebeau A, Canelo-Aybar C et al (2021) Recommendations from the European Commission initiative on breast cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. Br J Cancer 124(9):1503–1512. https://doi.org/10.1038/s41416-020-01247-z
doi: 10.1038/s41416-020-01247-z
pubmed: 33597715
pmcid: 8076250
Perou CM, Sorlie T, Eisen M (2000) Molecular portraits of human breast tumours. Nature 406:747–752
doi: 10.1038/35021093
pubmed: 10963602
Parker JS, Mullins M, Cheang MCU et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/JCO.2008.18.1370
doi: 10.1200/JCO.2008.18.1370
pubmed: 19204204
pmcid: 2667820
Eng A, McCormack V, dos-Santos-Silva I (2014) Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. https://doi.org/10.1371/journal.pmed.1001720
doi: 10.1371/journal.pmed.1001720
pubmed: 25202974
pmcid: 4159229
Kantelhardt EJ, Mathewos A, Aynalem A et al (2014) The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer 14:895. https://doi.org/10.1186/1471-2407-14-895
doi: 10.1186/1471-2407-14-895
pubmed: 25433805
pmcid: 4258259
McShane LM, Altman DG, Sauerbrei W et al (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. https://doi.org/10.1038/sj.bjc.6602678
doi: 10.1038/sj.bjc.6602678
pubmed: 16106245
pmcid: 2361579
Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366. https://doi.org/10.1200/JCO.19.02309
doi: 10.1200/JCO.19.02309
pubmed: 31928404
Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline focused update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
doi: 10.1200/JCO.2018.77.8738
pubmed: 29846122
Cheang MCU, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. https://doi.org/10.1093/jnci/djp082
doi: 10.1093/jnci/djp082
pubmed: 19436038
pmcid: 2684553
Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst 103(22):1656–1664. https://doi.org/10.1093/jnci/djr393
doi: 10.1093/jnci/djr393
pubmed: 21960707
pmcid: 3216967
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
doi: 10.1111/j.1365-2559.1991.tb00229.x
pubmed: 1757079
Berchtold E, Vetter M, Gündert M et al (2019) Comparison of six breast cancer classifiers using qPCR. Bioinformatics 35(18):3412–3420. https://doi.org/10.1093/bioinformatics/btz103
doi: 10.1093/bioinformatics/btz103
pubmed: 30759193
Hadgu E, Seifu D, Tigneh W et al (2018) Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health 18(1):40. https://doi.org/10.1186/s12905-018-0531-2
doi: 10.1186/s12905-018-0531-2
pubmed: 29444670
pmcid: 5813361
Kensler KH, Sankar VN, Wang J et al (2018) PAM50 molecular intrinsic subtypes in the nurses’ health study cohorts. Cancer Epidemiol Biomark Prev 28(4):798–806. https://doi.org/10.1158/1055-9965.EPI-18-0863
doi: 10.1158/1055-9965.EPI-18-0863
Sweeney C, Bernard PS, Factor RE et al (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomark Prev 23(5):714–724. https://doi.org/10.1158/1055-9965.EPI-13-1023
doi: 10.1158/1055-9965.EPI-13-1023
Newman LA (2014) Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 23(3):579–592. https://doi.org/10.1016/j.soc.2014.03.014
doi: 10.1016/j.soc.2014.03.014
pubmed: 24882352
Allott EH, Shan Y, Chen M et al (2020) Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Breast Cancer Res Treat 179(1):185–195. https://doi.org/10.1007/s10549-019-05442-2
doi: 10.1007/s10549-019-05442-2
pubmed: 31535320
Sengal AT, Haj Mukhtar NS, Vetter M et al (2018) Comparison of receptor-defined breast cancer subtypes between German and Sudanese women: a facility-based cohort study. J Glob Oncol 4:1–12. https://doi.org/10.1200/JGO.2017.010082
doi: 10.1200/JGO.2017.010082
pubmed: 30241184
Miyagawa Y, Miyake T, Yanai A et al (2015) Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer 22(4):399–405. https://doi.org/10.1007/s12282-013-0493-z
doi: 10.1007/s12282-013-0493-z
pubmed: 24000037
Kwan ML, Kroenke CH, Sweeney C et al (2015) Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer 15:278. https://doi.org/10.1186/s12885-015-1263-4
doi: 10.1186/s12885-015-1263-4
pubmed: 25884832
pmcid: 4403771
Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. https://doi.org/10.1073/pnas.191367098
doi: 10.1073/pnas.191367098
pubmed: 11553815
pmcid: 58566
Jorns JM (2019) Breast cancer biomarkers: challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation. Arch Pathol Lab Med 143(12):1444–1449. https://doi.org/10.5858/arpa.2019-0205-RA
doi: 10.5858/arpa.2019-0205-RA
pubmed: 31373514
Ziegenhorn H-V, Frie KG, Ekanem I-O et al (2020) Breast cancer pathology services in Sub-Saharan Africa: a survey within population-based cancer registries. BMC Health Serv Res. https://doi.org/10.1186/s12913-020-05752-y
doi: 10.1186/s12913-020-05752-y
pubmed: 33008380
pmcid: 7531092
Balic M, Thomssen C, Würstlein R et al (2019) St. Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 14(2):103–110. https://doi.org/10.1159/000499931
doi: 10.1159/000499931
pubmed: 31798382
pmcid: 6886108
Jensen M-B, Lænkholm A-V, Nielsen TO et al (2018) The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Breast Cancer Res. https://doi.org/10.1186/s13058-018-1012-0
doi: 10.1186/s13058-018-1012-0
pubmed: 30053900
pmcid: 6062869
Chia SK, Bramwell VH, Tu D et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465–4472. https://doi.org/10.1158/1078-0432.CCR-12-0286
doi: 10.1158/1078-0432.CCR-12-0286
pubmed: 22711706
pmcid: 3743663
Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767. https://doi.org/10.1172/JCI45014
doi: 10.1172/JCI45014
pubmed: 21633166
pmcid: 3127435
Hartung C, Porsch M, Stückrath K et al (2021) Identifying high-risk triple-negative breast cancer patients by molecular subtyping. Breast Care 16(6):637–647. https://doi.org/10.1159/000519255
doi: 10.1159/000519255
pubmed: 35082572
pmcid: 8740062
Getachew S, Addissie A, Seife E et al (2022) Breast nurse intervention to improve adherence to endocrine therapy among breast cancer patients in South Ethiopia. Oncologist 27(8):e650–e660. https://doi.org/10.1093/oncolo/oyac081
doi: 10.1093/oncolo/oyac081
pubmed: 35524760
pmcid: 9355816